OncoMatch/Clinical Trials/NCT06768489
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Official title: A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or in Combination With Pomalidomide for Multiple Myeloma
Is NCT06768489 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies multiple treatments including JNJ-79635322 and Daratumumab for multiple myeloma.
Treatment: JNJ-79635322 · Daratumumab · Pomalidomide · Lenalidomide — The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \[RP2Ds\]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor — multiple myeloma
including a proteasome inhibitor (PI) and an inhibitor, immunomodulatory drug (IMiD) therapy for the treatment of multiple myeloma (MM)
Must have received: immunomodulatory drug — multiple myeloma
including a proteasome inhibitor (PI) and an inhibitor, immunomodulatory drug (IMiD) therapy for the treatment of multiple myeloma (MM)
Must have received: proteasome inhibitor — multiple myeloma
including a PI and lenalidomide
Must have received: lenalidomide (lenalidomide) — multiple myeloma
including a PI and lenalidomide
Cannot have received: CD3-redirecting therapy
Prior treatment with CD3-redirecting therapy
Cannot have received: therapy for AL amyloidosis
Prior therapy for AL amyloidosis or multiple myeloma
Cannot have received: therapy for multiple myeloma
Prior therapy for AL amyloidosis or multiple myeloma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Colorado Blood Cancer Institute · Denver, Colorado
- Winship Cancer Institute Emory University · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06768489 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD3-redirecting therapy, therapy for AL amyloidosis, therapy for multiple myeloma disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages